Side-by-side · Research reference

PEG-MGFvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED2/69 cited

BPhase 3HUMAN-REVIEWED8/39 cited

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

PEG-MGF

Thymosin α-1

Primary target

IGF-1 receptor on muscle satellite cells and myocytes

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Partially bypassed — does not require hepatic IGF-1 synthesis

—

Origin

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

Unknown — no long-term human immunogenicity data

—

02Dosage Protocols

Parameter

PEG-MGF

Thymosin α-1

Research dose range

100–200 mcg

Extrapolated from animal models; no validated human protocols.

—

Frequency

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

2× weekly (Mon/Thu typical)

Half-life

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

~2 hours plasma; tissue effect days

Evidence basis

Animal / mechanistic

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Reconstitution

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

Sterile water for injection per vial label

PEG molecular weight

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

—

Timing

Within 30–60 min post-training

Aligns with endogenous MGF window.

No specific time

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

Duration

—

6–12 months for chronic indications

03Metabolic / Fat Loss Evidence

Parameter

PEG-MGF

Thymosin α-1

Primary target

Muscle tissue (satellite cells, myocytes) — not adipose-specific

—

Indirect metabolic effect

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

—

Body composition

Lean mass preservation / hypertrophy focus

—

Fat loss evidence

No direct human or animal RCT data for PEG-MGF-driven fat reduction

—

04Side Effects & Safety

Parameter

PEG-MGF

Thymosin α-1

Injection site reaction

Erythema, induration (common with SQ peptides)

Erythema, mild discomfort

Hypoglycemia risk

IGF-1 axis activation can lower blood glucose

—

IGF-1R overstimulation

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

—

Fluid retention

Possible with IGF-1 pathway activation (dose-dependent)

—

PEG accumulation

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

—

Antibody formation

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

—

Cancer risk

IGF-1 axis stimulation contraindicated in active malignancy

No signal — used as adjuvant in oncology

Human safety data

Absent — no published human trials for PEG-MGF

—

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Pregnancy / OB

—

Avoid

Absolute Contraindications

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

PEG-MGF

Thymosin α-1

1. Reconstitution

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

2× weekly, e.g. Monday + Thursday.

4. Storage

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair

Thymosin α-1

— no documented stacks